160 Health 02656Prospectus Information

Prospectus & Stock Connect
返回 Prospectus Allotment Results Allotment Profile Expected Lots Subscription Calculator Financials Cibo Flash
Data layers Raw facts Calculated Model prediction AI interpretation
IPO Timeline Raw facts
Broker Deadline
2025-09-12
Morning deadline
HKEX Deadline
2025-09-12
Noon deadline
Broker Results (T-2)
2025-09-15
Some brokers release in afternoon
Grey Market (T-1)
2025-09-16
Afternoon
HKEX Allotment (T-1)
2025-09-16
Evening
Registrar Allotment (T-1)
2025-09-16
Evening
Listing Day (T)
2025-09-17
First day of trading
Company Overview
Stock Name160 Health
Stock Code02656
Company Full Name160 Health International Limited
IndustryHealthcare
Principal ActivitiesWe are an experienced Chinese wholesaler of pharmaceutical and health products and a leading integrated digital healthcare service provider. We provide customers with a variety of pharmaceutical and health products, as well as comprehensive digital healthcare solutions. Under our wholesale and retail model, we offer a range of high-quality pharmaceutical and health products to meet the diverse needs of our customers. In addition, we also provide digital healthcare solutions through our online healthcare service platform, the Health 160 platform, empowering various platform participants across the entire healthcare industry chain (mainly including enterprise customers, healthcare institutions, medical and nursing personnel, individual users and third-party merchants), and promoting the digital transformation of China’s healthcare industry.
Listing Date2025-09-17
Listing Rules EraNew Rules (after Aug 2025)
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國 深圳市 南山區 南山街道 東濱路4078號 永新時代廣場 2號樓9層、11至12層
Business Address (Hong Kong)香港 銅鑼灣 勿地臣街1號 時代廣場 二座31樓
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitewww.91160.com
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo
Offering Information
Offering Mechanism Mechanism B
Offer PriceHK$ 11.89 / shares
Offer Price RangeFinal offer price only, no range
Lot Size250 shares
Entry ThresholdHK$ 2,972
Par ValueRMB 2e-06 / shares
Offer Period2025-09-09 to 2025-09-12
Global Offering Shares33,645,500 shares
HK Public Offer Shares (Initial)3,364,750 shares (10.0%)
Public Offer Lots (Initial)13,459lots (6,729lots, 6,730lots)
International Placing Shares (Initial)30,280,750 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO336,452,810 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)SHENWAN HONGYUAN CAPITAL (H.K.) LIMITED CE ABC209
Cornerstone ShareNo cornerstone investors
Clawback TiersMechanism B: no clawback
Reallocation OptionNo
Total Global Offering SizeHK$ 400,044,995
Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 250 HK$ 2,972
2 lots 500 HK$ 5,945
3 lots 750 HK$ 8,918
4 lots 1,000 HK$ 11,890
5 lots 1,250 HK$ 14,862
6 lots 1,500 HK$ 17,835
7 lots 1,750 HK$ 20,808
8 lots 2,000 HK$ 23,780
9 lots 2,250 HK$ 26,752
10 lots 2,500 HK$ 29,725
20 lots 5,000 HK$ 59,450
30 lots 7,500 HK$ 89,175
40 lots 10,000 HK$ 118,900
50 lots 12,500 HK$ 148,625
60 lots 15,000 HK$ 178,350
70 lots 17,500 HK$ 208,075
80 lots 20,000 HK$ 237,800
90 lots 22,500 HK$ 267,525
100 lots 25,000 HK$ 297,250
120 lots 30,000 HK$ 356,700
140 lots 35,000 HK$ 416,150
160 lots 40,000 HK$ 475,600
180 lots 45,000 HK$ 535,050
200 lots 50,000 HK$ 594,500
240 lots 60,000 HK$ 713,400
280 lots 70,000 HK$ 832,300
320 lots 80,000 HK$ 951,200
360 lots 90,000 HK$ 1,070,100
400 lots 100,000 HK$ 1,189,000
600 lots 150,000 HK$ 1,783,500
800 lots 200,000 HK$ 2,378,000
1,000 lots 250,000 HK$ 2,972,500
1,200 lots 300,000 HK$ 3,567,000
1,600 lots 400,000 HK$ 4,756,000
Pool B
Lots SubscribedShares SubscribedSubscription Amount (HKD)
2,000 lots 500,000 HK$ 5,945,000
2,400 lots 600,000 HK$ 7,134,000
3,200 lots 800,000 HK$ 9,512,000
4,000 lots 1,000,000 HK$ 11,890,000
4,800 lots 1,200,000 HK$ 14,268,000
6,729 lots 1,682,250 HK$ 20,001,952
Stock Connect Inclusion
HK Market Cap HK$ 17.53B
Analysis Result Already included in Stock Connect (both, shenzhen, shanghai)
Valuation & Financials
Market Cap (at Offer Price)HK$ 4,498,000,000
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot applicable (loss-making)
Profit/Loss StatusNet loss RMB 108.2 million (2024)
Period-End Cash BalanceRMB 37.7 million
Listing Expenses~HK$ 86,400,000
Listing Expenses / Funds Raised~19.2%
Total Pre-IPO InvestmentRMB 733.4 million
First Day Performance
First Day CloseHK$ 28.22
First Day OpenHK$ 29.98
First Day Change137.34%
First Day Volume7081940.0
First Day Turnover199579000.0
Use of Proceeds
Use of Proceeds1、約40.0%（或145.3百萬港元）將用于進一步擴大醫療資源覆蓋面，增加平臺流量； 2、約30.0%（或109.1百萬港元）將用于加強研發能力； 3、約10.0%（或36.4百萬港元）將用于豐富產品及服務種類并探索增值服務； 4、約10.0%（或36.4百萬港元）將用于有選擇地進行戰略合作及收購； 5、約10.0%（或36.4百萬港元）將用作營運資金及一般企業用途。
Underwriting Syndicate
Joint Sponsors (2)
SHENWAN HONGYUAN CAPITAL (H.K.) LIMITED CE ABC209 Zero2IPO Capital Limited CE BRH906
Sponsor cum Overall Coordinator (1)
SHENWAN HONGYUAN SECURITIES (H.K.) LIMITED CE AAC927
Overall Coordinators (2)
SHENWAN HONGYUAN SECURITIES (H.K.) LIMITED CE AAC927 Zero2IPO Securities Limited CE BNF723
Joint Global Coordinators (2)
SHENWAN HONGYUAN SECURITIES (H.K.) LIMITED CE AAC927 Zero2IPO Securities Limited CE BNF723
Joint Bookrunners (12)
SHENWAN HONGYUAN SECURITIES (H.K.) LIMITED CE AAC927 Zero2IPO Securities Limited CE BNF723 ABCI CAPITAL LIMITED CE AWL249 BOCI ASIA LIMITED CE AET863 Eddid Securities and Futures Limited CE BHT550 INNOVATION SECURITIES CO., LIMITED CE BGN336 VAST HARBOUR SECURITIES LIMITED CE AWT951 SOUTH CHINA SECURITIES LIMITED CE AAA874 ZHONGTAI INTERNATIONAL SECURITIES LIMITED CE BAA855 Livermore Holdings Limited CE BJN764 uSmart Securities Limited CE BJA907 VALUABLE CAPITAL LIMITED CE AUL711
Joint Lead Managers (12)
SHENWAN HONGYUAN SECURITIES (H.K.) LIMITED CE AAC927 Zero2IPO Securities Limited CE BNF723 ABCI Securities Company Limited CE ACX411 BOCI ASIA LIMITED CE AET863 Eddid Securities and Futures Limited CE BHT550 INNOVATION SECURITIES CO., LIMITED CE BGN336 VAST HARBOUR SECURITIES LIMITED CE AWT951 SOUTH CHINA SECURITIES LIMITED CE AAA874 ZHONGTAI INTERNATIONAL SECURITIES LIMITED CE BAA855 Livermore Holdings Limited CE BJN764 uSmart Securities Limited CE BJA907 VALUABLE CAPITAL LIMITED CE AUL711
Capital Market Intermediaries (13)
SHENWAN HONGYUAN SECURITIES (H.K.) LIMITED CE AAC927 Zero2IPO Securities Limited CE BNF723 ABCI CAPITAL LIMITED CE AWL249 ABCI Securities Company Limited CE ACX411 BOCI ASIA LIMITED CE AET863 Eddid Securities and Futures Limited CE BHT550 INNOVATION SECURITIES CO., LIMITED CE BGN336 VAST HARBOUR SECURITIES LIMITED CE AWT951 SOUTH CHINA SECURITIES LIMITED CE AAA874 ZHONGTAI INTERNATIONAL SECURITIES LIMITED CE BAA855 Livermore Holdings Limited CE BJN764 uSmart Securities Limited CE BJA907 VALUABLE CAPITAL LIMITED CE AUL711
Stabilizing Manager (1)
SHENWAN HONGYUAN CAPITAL (H.K.) LIMITED CE ABC209
Service Providers
RoleInstitution
Legal Advisor to Company 天元律师事务所（有限法律责任合伙）
上海澄明则正律师事务所
Harney Westwood & Riegels
Legal Advisor to Sponsors/Underwriters 欧华律师事务所
汉坤律师事务所
Jingtian & Gongcheng
Auditor and Reporting Accountant 罗兵咸永道会计师事务所
Industry Advisor Frost & Sullivan (Beijing) Inc., Shanghai Branch Co.
Receiving Banks 招商永隆银行
Cornerstone Investors
This stock has no cornerstone investors.
Directors & Management
Chairman羅寧政
Company Secretary唐世華
Executive Director (4)
#NameEnglish NameType
1 罗宁政 — Executive Director
2 冀翠琳 — Executive Director
3 黄浪 — Executive Director
4 王立法 — Executive Director
Non-Executive Director (2)
#NameEnglish NameType
1 张如协 — Non-Executive Director
2 孙萌 — Non-Executive Director
Independent Non-Executive Director (3)
#NameEnglish NameType
1 邹钧 — Independent Non-Executive Director
2 徐卫国 — Independent Non-Executive Director
3 范明 — Independent Non-Executive Director
Major Shareholders
Major Shareholders & HoldingsMr. Luo holds 102,912,905 shares (representing 30.59%) through Luo Holdings Limited and controls approximately 3.49% of the voting rights through a voting agreement. 傅哲寬 is deemed to have an interest in 51,701,065 shares (representing 15.37%), including entities controlled through 啟賦基金 and LFL Limited held by his spouse 林芳荔. 啟賦私募基金管理有限公司 holds 43,688,810 shares (representing 12.99%).
AI AI 市场洞察 AI interpretation deepseek-v4-pro · AI-generated
!
以下内容由AI模型基于历史IPO数据自动生成。不构成任何投资建议、招揽或推荐。过往申购模式和上市后表现不保证未来结果。数据可能存在不准确之处——在任何投资决策前，请务必查阅港交所官方文件和招股说明书。

市场情绪

健康160录得751.77倍超额认购，市场申购热情极为高涨，反映出医疗健康板块的强劲吸引力。一手（250股）中签率仅12.72%，竞争激烈程度远超近年平均水平；最终发售价11.89港元，在炽热需求下或已按区间上限定价。

申购档位分析

甲尾（300手）期望中签仅0.29手，而乙头（400手）可稳获1手，档位效率显著倒挂，甲组资金利用率偏低。若考虑乙组获取分配所需股数门槛及中签手数，乙头较甲尾呈现出更优的成本效益，但不同券商手续费结构各异，实际成本可能不同。

申购人群画像

此次分配数据未提供合格申购人的人口画像明细，中国内地及香港参与比例均显示为0，可能因数据源未完整披露，无法进行地域集中度分析。投资者应以港交所后续发布的详尽权益披露公告为准。

AI生成内容，仅供信息参考，不构成投资建议。请以官方文件为准。
// About this page //

This page shows 160 Health (02656) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements.

Disclaimer

Site Nature: This website (cibo.hk) is an independent technology product showcase platform established by Panda Securities Limited (CE Number: BNC380). This website itself and all content displayed herein do not constitute and are not involved in any regulated activity or licensed service.

Not Investment Advice: The data on this page is automatically extracted from prospectus PDFs by AI and may contain omissions or errors. All information and data on this page are sourced from prospectuses and related historical documents, are not real-time data, and will not be automatically updated, reflecting historical information at the time of prospectus publication. All content is provided solely for AI tool analysis learning exchange and technical reference purposes, and absolutely does not constitute any investment advice, offer to buy or sell, solicitation, recommendation, or guarantee. The output of this AI analysis tool should not be interpreted as investment opinion.

Decision Responsibility: Users should make investment decisions based on their own independent judgment and consult independent licensed financial advisors when needed. Neither the Company nor this AI analysis tool shall bear any responsibility for any investment decisions made by users based on the information on this page.

Separation from Panda Securities Official Website: The content of this website is strictly distinct from the SFC-regulated licensed services provided by Panda Securities' official website (fafa.hk). No securities trading or account opening or other regulated operations can be conducted through this website.

Panda Securities Limited is a licensed corporation regulated by the Hong Kong SFC (CE Number: BNC380) and a Hong Kong Exchange Participant (Participant ID: 02229). Use of this website constitutes acceptance of this disclaimer.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect